ABSTRACT. A rabbit model of group B Streptococcal (GBS) shock was used to study the effects of prostaglandin synthetase inhibition on the hemodynamic and hematologic response to GBS shock. The infusion of heat-killed GBS in groups I and I1 produced significant decreases in mean arterial pressure, neutrophil counts, and platelet counts ( p < 0.05), and significant rises in concentrations of thromboxane B2 and 6-KetoPGFla, the stable metabolites of thromboxane A2 and prostacyclin ( p < 0.05). Administration of indomethacin (4 mg/kg) after GBS infusion (group 11) was associated with a significant rise in mean arterial pressure and a significant decline in thromboxane B2 and 6-Keto-PGFla concentrations ( p < 0.05) but had no effect This work was funded by a grant from the Alabama Chapter American Heart Association and by NIH Grant HL2871 1.
ABSTRACT. A rabbit model of group B Streptococcal (GBS) shock was used to study the effects of prostaglandin synthetase inhibition on the hemodynamic and hematologic response to GBS shock. The infusion of heat-killed GBS in groups I and I1 produced significant decreases in mean arterial pressure, neutrophil counts, and platelet counts ( p < 0.05), and significant rises in concentrations of thromboxane B2 and 6-KetoPGFla, the stable metabolites of thromboxane A2 and prostacyclin ( p < 0.05). Administration of indomethacin (4 mg/kg) after GBS infusion (group 11) was associated with a significant rise in mean arterial pressure and a significant decline in thromboxane B2 and 6-Keto-PGFla concentrations ( p < 0.05) but had no effect on GBS-induced hematologic alterations. Indomethacin administration before GBS infusion (group 111) prevented alterations in mean arterial pressure and was associated with a decrease in thromboxane B2 and 6-Keto-PGFla concentrations. Indomethacin in group 111 did not prevent neutropenia and thrombocytopenia and may have exacerbated neutropenia. Alteration of experimental GBS shock with prostaglandin synthetase inhibition produces disparate hemodynamic and hematologic response. Neonatal GBS sepsis produces severe hemodynamic and hematologic manifestations (1) . The clinical findings of shock, acidosis, neutropenia, and marrow granulocyte depletion are thought to be correlates of high mortality in GBS sepsis (2) . Although arachidonic acid metabolites have been strongly implicated as modulators of the septic shock process (3), only Rojas et al. (4) have directed specific attention to possible interactions between PG endoperoxide products and the hematologic alterations of GBS sepsis. In their sheep lung lymph model, an extract of GBS produced granulocytopenia which was not altered by the prior administration of IND. These data suggest a lack of association between PG endoperoxide products and the development of neutropenia. However, this model was not designed to produce septic shock and therefore it could not be used to evaluate the possible influence of PG synthetase inhibition on neutropenia through modulation of septic shock. In addition, no studies have evaluated the possibility that PG synthetase inhibitors might exacerbate GBS-associated hematologic changes.
The purpose of this study was to define the role of PG endoperoxide products in modulating the hemodynamic and hematologic alterations of experimental GBS shock, and to further define how PG synthetase inhibition might alter the manifestations of the shock process.
MATERIALS AND METHODS
Preparation of GBS. A strain of GBS isolated from the blood of an infant dying with shock was used in all studies. Bacterial isolates were frozen at -20" C between isolation and use in studies. Before each series of experiments the organism was passed in a mouse, and isolated colonies from a heart blood subculture were grown overnight on blood agar. Bacteria were suspended in sterile, nonpyrogenic saline to a quantified density of 10" CFU per ml and then heat-killed at 100" C for 15 min. CFU were determined by quantitative subcultures, and complete heat-killing was documented by subculturing after heat killing.
Animal preparation. Following intravenous pentobarbitol anesthesia (50 mglkg), adult New Zealand White rabbits underwent tracheostomy and were placed on a small animal ventilator. Femoral arterial and venous catheters were inserted for measurement of the following: MAP, heart rate, arterial blood gases, total leukocvte counts annd differentials. vlatelet counts. and concentrations of TB2 and 6KPGFla, the'siable metabolites of thromboxane A2 and prostacyclin, respectively. Animals were hyperventilated to an alkalotic pH to minimize the anticipated effects of GBS-induced acidosis on MAP.
Experimental sequence. Four groups of animals were studied.
In groups I (n = 8) and I1 (n = 9) basal values for MAP, TB2, 6-KPGFla, neutrophil count, and platelet count were obtained, followed by infusion of heat-killed GBS (10" organismslkg) over 60 min. After MAP fell by 5096, repeat samples for TB2, 6-KPGFla, neutrophil count, and platelet count were obtained. This was followed by the administration of IND (4 mg/kg) (group 11) or drug vehicle (group I). Additional samples for determination of TB2 and 6-KPGFla levels, and neutrophil and platelet counts were obtained 60 min after IND or vehicle infusion. In group I11 (n = 7) MAP, TB2, and 6-KPGFla concentrations, and hematologic values were obtained in the basal state, after IND pretreatment (4 mg/kg), and 60 min after initiation of GBS infusion. Control animals (group IV, n = 6) were sampled for the same hemodynamic, hematologic, and PG variables in the basal state, 60 min after the initiation of a sterile, nonpyrogenic saline infusion, and 60 min after drug vehicle infusion.
Laboratory determinations. Total white blood cell counts and platelet counts were determined on a model S+ Coulter Counter. Peripheral blood absolute neutrophil counts were performed by a registered medical technologist. TB2 and 6-WGFla concentrations were assayed using standardized radioimmunoassay kits from New England Nuclear.
Statistical evaluation. Statistical comparisons of data were performed using one-way analysis of variance and randomized block design analysis of variance for unpaired and paired comparisons respectively, Duncan's test, and x2 analysis. A p value of < 0.05 was considered significant. Table 1 lists the results for MAP, TB2, 6-WGFla, neutrophil counts, and platelet counts for the four study groups. Mean arterial pressure fell significantly after GBS infusion in groups I and 11. Administration of drug vehicle in group I did not alter the MAP, but in group I1 animals IND administration produced a significant rise of MAP to near the basal state. Animals infused with GBS after pretreatment with IND (group 111) and those infused only with saline (group IV) showed no significant alterations of MAP. In groups I and 11, infusion of GBS produced increases in TB2 and 6-KPGFla concentrations which were significantly elevated above the basal value. In group I, TB2 and 6-KPGFla concentrations remained elevated after drug vehicle infusion, although only the 6-KPGFla value was significantly different from the basal state. In group I1 IND treatment resulted in a significant decline in TB2 and 6-KPGFla concentrations. Levels of both PG endoperoxide products fell from basal values in group 111 after IND infusion, even in the presence of GBS administration. Control animals showed no changes in concentrations of either PG endoperoxide product.
RESULTS
In groups I, 11, and 111 both neutrophil and platelet counts fell dramatically after the administration of GBS. Neither pre-(group 111) nor post-GBS (group 11) administration of IND appeared to prevent the significant fall in these hematologic values. IND Table 1 . Baseline and uostintewention values for MAP, pretreatment in group I11 was associated with a significantly lower neutrophil count after GBS infusion than when only GBS and drug vehicle were given (group I) ( p < 0.05). In addition, animals in groups I and I1 had significantly less frequent total neutrophil depletion than in group I11 (data not shown). Group IV animals demonstrated a statistically significant rise in neutrophi1 count and a modest decline in platelet count. In none of the groups was a significant change in immature neutrophil count or immaturelmature neutrophil ratio found. Table 2 provides arterial pH, blood gases, and calculated bicarbonate concentrations on the four groups. A significant PEEVY decline in pH occurred in groups I, 11, and 111 after administration of GBS although the magnitude of decline was less in the INDpretreated animals (group 111). A significant fall in Pa02 occurred in groups I and I1 and a significant rise in Paco2 occurred in group 11. No statistically significant changes in Pa02 or Paco2 occurred in IND-pretreated animals or saline-infused controls. All groups showed a significant decline in calculated bicarbonate values over time. However, the magnitude of the decline was greatest in groups I and 11, a finding consistent with the alterations in pH in those groups.
DISCUSSION
Several investigators have shown an association between PG endoperoxide products or PG synthetase inhibition and the hemodynamic manifestations of GBS shock (5) (6) (7) . Our present data demonstrate that in experimental GBS shock systemic hypotension is associated with changes in levels of PG metabolites, and that these changes are preventable or significantly altered by IND treatment. In group I, drug vehicle values for TB2 are not significantly different from baseline within the group, but were significantly different from the values for the other three groups. This late fall in TB2 in group I may reflect poststimulation exhaustion of platelet TB2 production. The significant fall in TB2 in group I1 after indomethacin suggests that a major reduction in TB2 production is still achievable through PG synthetase inhibition.
The relationships of peripheral neutrophil and platelet depletion to the development of GBS-shock and PG production have not been well studied. Our data demonstrate three important points in this regard: 1) the lack of correlation between TB2 and 6-KPGFla concentrations and neutrophil count in group I1 and the development of neutropenia in group I11 support the idea that neutropenia occurs independently of PG production; 2) neutropenia in group 111 demonstrates that shock is not a necessary antecedent of GBS-induced neutropenia; and 3) a stable MAP in group 111 demonstrates that shock is not a sequelae of GBS-induced neutropenia.
In group 111, the lower mean neutrophil count and the greater frequency of total peripheral neutrophil depletion could be chance occurrences of no clinical or scientific significance. However, they suggest that inhibition of PG synthetase prior to GBS administration may alter peripheral neutrophil removal. In vitro studies showing IND enhancement of arachidonate-induced neutrophil aggregation (8) and IND inhibition of GBS-induced neutrophil aggregation (9) lend conflicting information, but support the idea that PG metabolism may affect the aggregation process.
The significant rise in neutrophil count in group IV was thought to be due to demargination induced by the stress of anesthesia and instrumentation.
In summary, PG synthetase inhibition with IND reduced GBSinduced production of PG endoperoxide products and altered the hemodynamic response to experimental GBS shock. GBSinduced neutropenia and thrombocytopenia was not prevented by IND, although pretreatment with IND may have enhanced peripheral neutrophil depletion. Further in vitro and in vivo studies are needed to elucidate the role of PG synthetase inhibitors in modulating the hematologic response to GBS shock.
